48 results about "Aceclofenac" patented technology

The invention provides an improved method used for preparing aceclofenac. The improved method is characterized in that (1) the method takes diclofenac sodium and tert-butyl chloroacetate as raw materials and iodide as a catalyst, and heats the substances to carry out condensation reaction; (2) the method takes tert-butyl aceclofenac as a raw material to carry out acidolysis reaction under the action of phenol and acid, and obtains aceclofenac crystal after post treatment and fine purification; and the total yield of both steps is above 88 percent and the content is over 99.2 percent (detected by HPLC). The improved method increases the yield and the content, and has short reaction time, simple and convenient operation and mild reaction conditions; and a reaction reagent is easy to recycle, so the improved method reaches the effects of lowering cost and reducing environment pollution.

There are provided compositions and preparation methods for bioavailable oral aceclofenac dosage forms. More particularly, the compositions containing water-insoluble aceclofenac, a polymeric base selected from the group consisting of polyvinyl, methyl cellulose, ethyl cellulose, hydroxypropylmethylcellulose, carboxy methyl cellulose, glyceryl monostearate, carbamer, and poloxamer, and surfactant. The compositions of the present invention can be formulated into compressed particles, granules, tablets, capsules or even semisolid preparations, which significantly increase the bioavilablity due to the improvement of dissolution of the drug in gastrointestinal tract, and reduce the manufacturing cost by simple process.

The invention relates to a drug sustained-release preparation and its preparation method, in particular to an aceclofenac sustained-release tablet and its preparation method, which comprises the following ingredients according to the weight percentage: aceclofenac of 60 to 95 per cent, skelecton retarder of 3 to 30 per cent, adhesive of 1 to 10 per cent and lubricant of 0.5 to 15 per cent. The hydroxypropylmethyl cellulose and carboxyvinyl polymer are adopted as optimized skelecton retarder. With such a technical proposal in the invention, the one aceclofenac sustained-release tablet can be taken a day to effectively reduce the fluctuation of blood drug level, prolong the maintenance duration of effective blood drug level and lower down the incitement to gastrointestinal tract. Besides, the invention also provides the preparation method of the aceclofenac sustained-release tablet.

The invention discloses a salt compound formed through the aceclofenac and the organic base and the assemblage and the use. The general formula of the salt compound is AxR mH2O; wherein, A is the aceclofenac (CAS RN: 89796-99-6) and x is 1, 2; R is nitrogen organic base and can be amine and basic amino acid. The amine is most suitable for being selected from the Meglumine and trometamol; the basic amino acid is most suitable for being selected from the Arginine, Lysine, Ornithine, Histidine and Citrulline. The spatial configurations of the amino acids include the DL type, D type, L type and optimized L type; m is 0, 1, 2, 3, 4, 5 and 6. The compound and the assemblage to which the invention relates can be applied to the diseases such as the inflammation and pain, sprain, pull, and other soft tissue injuries and fever, etc., caused by the rheumatoid arthritis, rheumatoid arthritis, osteoarthritis, spondylitis, etc. of the human beings or animals.

The invention belongs to the field of medicine and pharmacology, and is Pharmaceuticals oral granule. The Aceclofenac granule is made by raw material drug aceclofenac, findings and disintegrant. The Aceclofenac granule is phenyl acetic acid non-steroidal anti-inflammatory agent. It has notable anti-inflammatory, analgesic and antipyretic effect. It applies to the treatment of various rheumatoid arthritis, atrophic arthritis, osteoarthritis and spondylitis. It is fit for pain and fever caused by various diseases, and the toxic and side effects is lower than other varieties. Aceclofenac has not granule in prior medicine market; it is innovative formula and benefit for absorbing drug to getting better curative effect and better taste. It is safe, reliable and new drug for treatment of acute, chronic pain and anti-inflammation.

Disclosed is a method for preparing aceclofenac enteric microcapsules, comprising dissolving eudragit II, hydroxypropylmethylcellulose phthalate (HPMCP) or cellulose acetate phthalate in acetone to acquire a solution A; then adding aceclofenac powder into the solution A and fully dissolving the aceclofenac powder to obtain a solution B, and acquiring a primary emulsion by placing the solution B in a flask and stirring; adding span 80 into liquid paraffin and fully stirring; adding the primary emulsion into the well-stirred liquid paraffin, heating up to 75 DEG C gradually while stirring, and acquiring microcapsules by stirring continuously while preserving the temperature; and washing the microcapsules by using n-hexane three times after filtering and drying to acquire the finished microcapsules. According to the invention, the aceclofenac slow-release enteric microcapsules are prepared by using a property that decomposition of a capsule wall material is influenced by pH values. Through controlling the capsule wall material, the following effects can be achieved: drugs are sent directionally to the small intestine and released slowly to gentle the plasma concentration, prolong the action time, and improve the curative effect; the dosing frequency can be reduced and the plasma concentration is maintained in the body; and an adverse reaction in the gastrointestinal tract is reduced effectively and patient compliance is also improved effectively.

The invention provides an aceclofenac bi-layer osmotic pump controlled release tablet and a preparation method thereof, belongs to the technical field of medicinal preparation. The osmotic pump preparation comprises a tablet core containing aceclofenac and a semipermeable coating membrane which is coated outside the tablet core and provided with orifices, the tablet core comprises a drug layer containing aceclofenac and a boosting layer; wherein, the drug layer comprises the following components: 200mg of aceclofenac, 100mg-300mg of suspension, 10mg-50mg of osmotic stress active substance and0.5 mg-2mg of lubricant; the boosting layer comprises 50mg-150mg of sweller and 5mg-30mg of osmotic stress active substance; the semipermeable coating membrane comprises the following components: 10g-20g of semipermeable high polymer material dissolved in 500ml of acetone and 2g-5g of water soluble pore former dissolved in 20ml of distilled water and the weight of the coating membrane is 5%-10% of the tablet core weight; laser or a power drill is used to drill the orifices on the drug-containing side of the coating tablet. The invention is characterized of less dosing frequency, convenient taking way, long lasting and stable curative effect and can be used to cure pains and inflammations caused by osteoarthritis, rheumatoid arthritis, ankylosing spondylitis and the like.

The invention discloses a compound enteric-coated preparation. The aceclofenac in the compound preparation is dissolved by intestines through a pharmacy means and paracetanol is guaranteed to release in stomach, so that stimulus and untoward effect of the aceclofenac in the compound preparation on the stomach are reduced, and the normal absorption of the paracetanol is guaranteed to improve the compliance of a patient.

The invention discloses a microwave-assisted preparation method of aceclofenac. The method is as follows: under the microwave condition, a compound 2 and a compound 3 are reacted to form a compound 4under the catalysis of KI; and under the microwave condition, a reaction of the compound 4 is carried out in a mixed solvent of formic acid and acetone. According to the method, the acidolysis of aceclofenac tert-butyl ester is carried out in the mixture of formic acid and acetone under the microwave condition, the acidolysis method has high selectivity, the fracture of the ethoxyl group in aceclofenac tert-butyl ester is reduced to the lowest limit, the conversion rate of the acidolysis reaction is high, the diclofenac content in the product is extremely small, the product is easy to refine,and the purity is high.

The invention discloses an aceclofenac pharmaceutical composition which contains the following raw materials: 10-150 portions of aceclofenac and 2.5-140 portions of organic base solvent. The composition also contains the following raw materials: 0-50 portions of pH modifying agent, 0-500 portions of osmotic pressure regulator, 0-600 portions of stabilizing agent, 0-100 portions of local acetanilide and 2000-10000 portions of water. The invention does also not contain phosphate, does not influence the calcium metabolism and the hormone secretory and increases the absorption of internal calcium and iron; and injection is dissolved by using common injection water or physiological saline without special menstruum.

The invention relates to an aceclofenac enteric-coated pellet capsule and a preparation method thereof, and belongs to the technical field of a drug preparation. The aceclofenac enteric-coated pellet capsule is prepared from aceclofenac enteric-coated pellets filling in a capsule shell. The aceclofenac enteric-coated pellet capsule is simple in preparation method, low in labor intensity, applicable to industrial production, beneficial to environmental protection, small in gastrointestinal stimulation on a sufferer, high in bioavailability, good in stability and the like.

The present invention relates to a controlled-release preparation administered orally once a day that exhibits an optimum pharmacological clinical effect, featuring two-layer tablets, dual tablets and multilayered tablets having a fast-release layer comprising aceclofenac, a water-soluble additive, a non-soluble additive, a solubilizer, a disintegrator and a filler, and a slow-release layer comprising aceclofenac, a slow-release base, a disintegrator, a binder, a filler, a fluidizer, a solubilizer and a lubricant.

The invention discloses a preparation process of novel aceclofenac. The preparation process of novel aceclofenac which is stated by the invention comprises filling diclofenac and toluene in a reaction bottle, stirring under the condition of outside temperature, dripping triethylamine until the solution is clarified, dripping tert-butyl bromoacetate to react for 3-4 hours when temperature is 50-60 DEG C, dripping 30% NaOH solution to alkalize after reaction, separating layers, scouring organic layer with water, drying with anhydrous sodium sulfate, filtering, steaming out organic solvent, dripping formic acid, reacting for 1 hour with 56-60 DEG C, dripping pure water when temperature is 0-5 DEG C, crystallizing for two hours, filtering and drying to obtain aceclofenac crystal (mp.151-152 DEG C). The process utilizes the advantages that tert-butyl is easy to be removed without the catalysis of palladium-charcoal and hydrogenization reaction, and tert-butyl is removed under the action of formic acid to obtain aceclofenac. The reaction can be conducted under smooth condition, which firstly improves reaction condition, secondly reduces environment pollution, and thirdly increases product yield.

The invention relates to an acedofenac-paracetamol pharmaceutical composite and a liposome solid preparation thereof and a preparation method thereof; the solid preparation comprises the liposome of acedofenac-paracetamol and the excipient which is accepted in pharmacy and the liposome comprises the following components according to the parts by weight percent: 1 part of acedofenac, 5 parts of paracetamol, 5-32 parts of soybean lecithin, 2-17 parts of cholesterol, 2.5-15 parts of sodium deoxycholate and 4-24 parts of poloxamer 188.

The invention relates to a method for producing aceclofenac tert-butyl ester. The method includes: allowing diclofenac sodium, tert-butyl bromoacetate, catalyst iodide and tetrabutylammonium hydrogensulfate to have reaction in water, slowly cooling, crystallizing, filtering, washing, and drying. The method is mild in reaction conditions, high in yield, capable of reducing waste liquid discharge,capable of avoiding the toxic effect of organic solvents on human bodies and the like.

The present invention relates to pharmaceutical compositions including a triphasic release system, which may be delayed release and/or extended release and/or modified release and/or immediate release, of at least three layers for the formation of at least one dosage unit. Each layer includes, as active pharmaceutical ingredients, at least one corticosteroid agent of the betamethasone type and/or the pharmaceutically acceptable salts thereof, at least one non-steroidal anti-inflammatory agent of the Aceclofenac type and/or the pharmaceutically acceptable salts thereof, and at least one pharmaceutically acceptable excipient. Also described is the novel production process. Said triphasic release system generates an enhanced treatment effect to combat inflammation and body pain.

The present invention discloses one kind of externally applied aceclofenac gel preparation and its preparation process. The externally applied aceclofenac gel preparation is compounded with aceclofenac 0.5-8 wt%, organic solvent 5-50 wt%, bacteriostat 0.001-10 wt%, pH regulator 0.01-2 wt%, carbomer 0.5-8 wt%, antioxidant 0.01-5 wt% and water for the rest. It is prepared through mixing the said ingredients. It is applied to the joint or other disease focus to result in obvious curative effect.

The invention discloses a pharmaceutical composition of aceclofenac and a pharmaceutical application thereof. The pharmaceutical composition of aceclofenac, disclosed by the invention, contains aceclofenac and a natural product compound (I) with a novel structure and separated from the dried root of rheum officinale. When the aceclofenac and the natural product compound (I) act separately, the treatment effect on chronic nephritis is relatively low; by combining the aceclofenac and the natural product compound (I), the treatment effect on chronic nephritis is remarkably improved; and the pharmaceutical composition can be developed into a medicine for treating chronic nephritis and has outstanding substantial characteristics and remarkable progress in comparison with the prior art.

The present invention relates to an association of active ingredients. More specifically: to an association of cyclobenzaprine and aceclofenac. Additionally, the present invention is also related to the use of aceclofenac and cyclobenzaprine, in association for the preparation of a medicine useful in the treatment of painful muscular diseases, as well as to a method of treatment of painful muscular diseases using an association of aceclofenac and cyclobenzaprine.

This invention is related to a pharmaceutical composition made up by the synergic combination of a nonsteroidal anti-inflammatory analgesic such as Aceclofenac or its pharmaceutically acceptable salts and an anti-inflammatory steroid agent such as the active ingredient Betamethasone or its pharmaceutically acceptable phosphate or dipropionate salts, which are formulated in a single dosing unit for topical, intramuscular or intravenous administration, which is indicated for the treatment of the localized pain of rheumatic diseases.